Bharat Biotech revealed the safety and efficacy analysis data from Phase-3 clinical trials of Covaxin, an indigenous vaccine intended to combat the deadly Covid-19 pandemic, on Saturday.
Bharat Biotech stated that the Indian-made Covaxin achieved overall effectiveness of 77.8% against symptomatic Covid-19 patients, citing pre-print results from the country’s largest efficacy trial.
According to the Hyderabad-based biotech company’s findings from the efficacy analysis, Covaxin also showed 93.4 percent effectiveness against severe symptomatic Covid-19 cases. Furthermore, Covaxin offers 65.2 percent protection against the B.1.617.2 or Delta strain, which was responsible for the country’s second wave of Covid-19.
Bharat Biotech claimed Covaxin demonstrated 63.6 percent safety and effectiveness against asymptomatic Covid-19 patients after the completion of its Phase-3 efficacy trial. Phase 2 vaccination studies are used to determine the vaccine’s safety, whereas Phase 3 trials are used to determine the vaccine’s efficacy and effectiveness.
The pre-print study of the total effectiveness rates of Covaxin after Phase-3 studies are as follows:
Asymptomatic cases: 63% efficacy
Mild, moderate, and severe cases: 78% efficacy
Severe Covid-19 cases: 93% efficacy
Delta variant: 65% efficacy
The Covaxin Phase-3 analysis, published on the medRxiv pre-print server, was carried out across 25 hospitals in India as trial sites.
In the final trials, volunteers received two intramuscular injections of either the Covid-19 vaccine or a placebo over the course of four weeks, utilizing a sponsor-supplied randomization system. According to the report, there were 25,800 participants ranging in age from 18 to 98 years old.
Along with Serum Institute’s Covishield and Russian-made Sputnik V, Bharat Biotech’s Covaxin is one of three vaccines presently being injected to the Indian populace. In January, Covaxin received clearance for emergency usage in the Indian population.
Post Your Comments